WASHINGTON (dpa-AFX) - Apricus Biosciences, Inc. (APRI) on Monday announced the sale of Totect, a marketed, injectable treatment for anthracycline extravasation, and NitroMist, an FDA-approved nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.
Totect was acquired by Biocodex USA, a subsidiary of a privately-held, French pharmaceutical company, Biocodex Laboratories. Under the deal, Apricus Bio received an upfront payment at closing and is eligible to receive royalties on net sales of Totect by Biocodex through 2016, in exchange for Apricus Bio's sale of its commercialization rights to Totect) in North America and South America.
NitroMist was acquired by privately held Mist Pharmaceuticals, LLC. Mist will receive rights to commercialize and market NitroMist in all countries outside the U.S., Canada and Mexico.
In line with its previously stated corporate strategy, Apricus Bio is focusing its resources on commercializing its lead product Vitaros for the treatment of erectile dysfunction, and on the development of Femprox for the treatment of female sexual arousal disorder.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de